Yang L1, Christensen T2, White J3, Sun F4 1Peking University Health Science Center, Beijing, China, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk, Zurich, Switzerland, 4Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China
Shih YCT1, Venier J1, Munsell M1, Cantor SB1, Elting LS1, Ravdin P2, Berry DA1 1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2Adjuvant! Online, San Antonio, TX, USA
Gibson TB1, Jing Y2, Bagalman E1, Cao Z1, Bates J2, Hebden T2, Forbes RA3, Doshi JA4 1Thomson Reuters, Ann Arbor, MI, USA, 2Bristol-Myers Squibb Company, Plainsboro, NJ, USA, 3Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ, USA, 4University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Liu FX1, Alexander GC2, Crawford SY3, Pickard AS3, Hedeker DR3, Walton S3 1Baxter Healthcare Corporation, Deerfield, IL, USA, 2University of Chicago, Chicago, IL, USA, 3University of Illinois at Chicago, Chicago, IL, USA
Suh HS1, Doctor J2, Hay JW3 1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2USC School of Pharmacy, Los Angeles, CA, USA, 3University of Southern California, Los Angeles, CA, USA
Kelton CM1, Guo JJ2, Safi A1, Yu Y1 1University of Cincinnati College of Business, Cincinnati, OH, USA, 2University of Cincinnati Medical Center, Cincinnati, OH, USA
Rubin J1, McGarry L1, Klugman K2, Strutton D3, Gilmore K1, Hwang S3, Rinaldi F4, Weinstein M5 1i3 Innovus, Medford, MA, USA, 2Rollins School of Public Health, Emory University, Atlanta, GA, USA, 3Pfizer Inc., Collegeville, PA, USA, 4Independent Consultant to Wyeth - Asia Pacific, London, UK, 5Harvard School of Public Health, Boston, MA, USA
Watkins J1, Sullivan S2, Ramsey S3, Wong E1, Veenstra D2, Burke W4, Roy Choudhury S1
1Premera Blue Cross, Mountlake Terrace, WA, USA, 2University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 4University of Washington, Department of Bioethics and Humanities, Seattle, WA, USA
Wong H1, Levit K2, Sun YC3
1Agency for Healthcare Research and Quality, Rockville, MD, USA, 2Thomson Reuters, Washington, DC, DC, USA, 3Thomson Reuters, Santa Barbara, CA, USA
Ishak K1, Stolar M2, Wang Y3, Alvarez P2, Hu MY3, Williams GC3, Ferguson J3, Aronson S4, Multz AS5, Dyke CM6, Getsios D7 1UnitedBioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Lexington, MA, USA, 3The Medicines Company, Parsippany, NJ, USA, 4Duke University School of Medicine, Durham, NC, USA, 5Albert Einstein College of Medicine, New Hyde Park, NY, USA, 6Brazosport Regional Health System, Lake Jackson, TX, USA, 7United BioSource Corporation, Halifax, NS, Canada
Kim MH1, Lin J2, Foltz Boklage SH3, Kreilick CA3 1Northwestern University, Chicago, IL, USA, 2sanofi-aventis U.S., Bridgewater, NJ, USA, 3ProUnlimited, Boca Raton, FL, USA
Djalalov S1, Yong J1, Saposnik G1, Musa Z2, Mendelson M3, Siminovitch K4, Black S5, Hoch J2 1St. Michael's Hospital, Toronto, ON, Canada, 2Cancer Care Ontario, Toronto, ON, Canada, 3Caledon Institute of Social Policy, Ottawa, ON, Canada, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Marshall DA1, Kulin NA1, Elkin EB2, Ferrusi IL1, Phillips K3 1McMaster University, Hamilton, ON, Canada, 2Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 3University of California, San Francisco, San Francisco, CA, USA
Jutkowitz E, Gitlin L, Pizzi LT
Thomas Jefferson University, Philadelphia, PA, USA
10:45AM-11:00AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
11:00AM-12:45PM
WELCOME & SECOND PLENARY SESSION
INCOMING PRESIDENTIAL ADDRESS Scott D. Ramsey MD, PhD Full Member and Professor, Fred Hutchinson Cancer Research Center, University of Washington,
Seattle, WA, USA
IS HEALTH OUTCOMES RESEARCH VALUABLE TO REAL DECISION MAKERS: A CANDID DISCUSSION WITH MEDICAL AND PHARMACY DIRECTORS
Despite its tremendous growth over the past 20 years, our field has not achieved the expected impact on health technology decisions in the United States and elsewhere. A panel of medical and pharmacy directors will be asked to provide their perspective on the value of health outcomes research, including where and how research findings are being used to make coverage decisions. Panelists will also provide recommendations on the use of health outcomes research in real decisions.
11:15 – 11:20 AM
Moderator: J. Jaime Caro MDCM, FRCPC, FACP, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA
11:20 – 11:30 AM
Speaker: Albert J. Rizzoli MD, Medical Director, Presbyterian Health Plan, Albuquerque, NM, USA
11:30 – 11:40 AM
Speaker: Kenneth L. Schaecher MD, Medical Director, SelectHealth, Salt Lake City, UT, USA
11:40 – 11:50 AM
Speaker: John Watkins RPh, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross and Clinical Associate Professor of Pharmacy, University of Washington, Seattle, WA, USA
11:50 – 12:00 PM
Speaker: Harold “Hank” H. Gardner MD, Founder, HCMS Group, Cheyenne, WY, USA
12:00 – 12:45 PM
DISCUSSION
12:45PM-1:15PM
ISPOR AWARDS PRESENTATION
1:15PM-2:45PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
1:30PM-2:30PM
EDUCATIONAL SYMPOSIUM (Sponsored by UBC)
COMPARATIVE EFFECTIVENESS & STANDARDS OF EVIDENCE: THE INTERSECTION OF SCIENCE, POLICY, REGULATION AND BUSINESSSymposium Description »
2:45PM-3:45PM
ISSUE PANELS – SESSION II
Clinical Outcomes Research Issues
2:45PM-3:45PM
IP5: PRAGMATIC CLINICAL TRIALS – HOW BROAD IS TOO BROAD AND HOW EARLY IS TOO EARLY? Moderator: C. Daniel Mullins PhD, Professor, Pharmacoeconomics, University of Maryland School of Pharmacy, Baltimore, MD, USA Panelists: Winston Wong PharmD, Associate Vice President, Pharmacy Management, CareFirst BlueCross BlueShield, Baltimore, MD, USA; Don P. Buesching PhD, US Outcomes Research Fellow, Eli Lilly and Company, Indianapolis, IN, USA; Jonathan Ratner PhD, Senior Economist, Westat, Rockville, MD, USA
Economic Outcomes Research Issues
2:45PM-3:45PM
IP6: DO END-OF-LIFE PRODUCTS DESERVE SPECIAL TREATMENT?: ISSUES AND POTENTIAL SOLUTIONS? Moderator: Donald Husereau MSc, Director, Project Development, Health Technology Assessment, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada. Panelists: Nicole Mittmann PhD, Executive Director, HOPE Research Centre and Scientist, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Marc L. Berger MD, Vice President, Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; Mark J. Sculpher PhD, Professor of Health Economics and Director of the Programme on Economic Evaluation and Health Technology Assessment, Centre for Health Economics, The University of York, York, UK
Health Policy Development Using Outcomes Research Issues
2:45PM-3:45PM
IP7: COST-EFFECTIVENESS ANALYSIS IN THE SOUTHWEST QUADRANT: ADOPTING MEDICAL TECHNOLOGY THAT COSTS LESS AND DOES LESS Moderator: Greg de Lissovoy PhD, MPH, Senior Research Scientist and Vice President, Health Technology, Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Bethesda, MD, USA Panelists: Peter J. Neumann ScD, Professor, Tufts University School of Medicine and Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; John F.P. Bridges PhD, Assistant Professor, Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD, USA; David W. Lee PhD, Senior Director, Health Economics - Americas, GE Healthcare, Waukesha, WI, USA
2:45PM-3:45PM
IP8: FINDING COMMON REQUIREMENTS AND ENDPOINTS FOR LICENSING AND REIMBURSEMENT AGENCIES Moderator: Guido Rasi MD, Director General, Italian Medicines Agency (AIFA), Rome, Italy Panelists: Hans-Georg Eichler, Senior Scientific Advisor, European Medicines Agency, London, United Kingdom; David Grainger MD, Global Public Policy Director, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA;Finn Børlum Kristensen MD, PhD, Director of Secretariat and Executive Committee Chair, EUnetHTA, Copenhagen, Denmark
3:45PM-4:00PM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
4:00PM-5:00PM
WORKSHOPS – SESSION III
Clinical Outcomes Research Issues
4:00PM-5:00PM
W15: SELECTING COMPARATORS AND OUTCOMES FOR COMPARATIVE EFFECTIVENESS STUDIES IN ONCOLOGY Discussion Leaders: C. Daniel Mullins PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland, School of Pharmacy, Baltimore, MD, USA; Russell W. Montgomery MHS, Project Manager, Center for Medical Technology Policy, Baltimore, MD, USA
Economic Outcomes Research
4:00PM-5:00PM
W16: IDENTIFYING AND PROJECTING PRODUCT VALUE THROUGH EARLY-PHASE CLINICAL-ECONOMIC MODELING Discussion Leaders: Ipek Özer-Stillman MS, Director, Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA; Jeffrey D. Miller MS, Senior Director, Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA; Bjorn Bolinder MBA, Head, Primary Care, Global Health Outcomes, Merck & Co., Kenilworth, NJ, USA; Mason W. Russell MAPE, Vice President, Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA
Health Care Policy Development Using Outcomes Research
4:00PM-5:00PM
W18: ENGAGING STAKEHOLDERS TO ENHANCE PERFORMANCE OF COMPARATIVE EFFECTIVENESS RESEARCH Discussion Leaders: Jean Slutsky PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Newell Mcelwee PharmD, Executive Director, US Outcomes Research, Merck & Co., Inc., North Wales, PA, USA; Eric Wall MD, MPH, Senior Medical Director, Qualis Health, Seattle, WA, USA; Jennifer Bright MPA, Executive Director, Society for Healthcare Epidemiology of America, Alexandria, VA, USA
Patient-Reported Outcomes/PREFERENCE-BASED Research
W20: DEVELOPING TOOLS FOR CONDUCTING OBSERVATIONAL DATABASE RESEARCH ACROSS A NETWORK OF REAL-WORLD DATA SOURCES Discussion Leaders: Marc Overhage MD, PhD, Director, Medical Informatics and Research Scientist, Regenstrief Institute, Inc., Indianapolis, IN, USA; Abraham G. Hartzema MSPH, PhD, FISPE, Professor and Eminent Scholar Perry A Foote Chair in Health Outcomes Research & Pharmacoeconomics, Department of Epidemiology and Biostatistics College of Public Health and Health, University of Florida, Gainesville, FL, USA; Vinit Nair MS, RPh, Director, Miami-Humana Health Services Research, Miami-Humana Health Services Research Center, Humana Inc, Miami, FL, USA; Greg Hess MD, MBA, MSc, Vice President for Health Economics / Outcomes Research & Chief Medical Officer, SDI Health, Plymouth Meeting , PA, USA
4:00PM-5:00PM
W21: PROSPECTIVE OBSERVATIONAL STUDIES: AVOIDING DESIGN PITFALLS USING PROCESS MAPS, DECISION-TREE METHODS, AND ELECTRONIC MEDICAL RECORDS Discussion Leaders: Kelly Hollis MBA, Senior Director Survey Research, RTI Health Solutions, Research Triangle Park, NC, USA; Margaret Mordin MS, Senior Director Regulatory and Health Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA; Pete Bechtel, President and CEO, eCast Corporation, Raleigh, NC, USA; Lori McLeod PhD, Head, Psychometrics, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA
5:15PM-6:15PM
WORKSHOPS – SESSION IV
Clinical Outcomes Research Issues
5:15PM-6:15PM
W22: PUBMED®/MEDLINE®/NLM: THE NEW AND IMPROVED LITERATURE SEARCH Discussion Leaders: Kristine Ogden, Research Manager, Global Health Economics & Outcomes Research, Lifecycle Sciences Group, ICON Clinical Research, San Francisco, CA, USA; Kimberly Miller PhD, Associate Director, Global Health Economics and Outcomes Research, Lifecycle Sciences Group, ICON Clinical Research, San Francisco, CA, USA; Alison Aldrich MSI, MPH, NN/LM PNR Technology Outreach Coordinator, Health Sciences Library, University of Washington, Seattle, WA, USA; Ione Auston MLS, Librarian, National Information Center on Health Services Research (NICHSR), National Library of Medicine (NLM), Bethesda, MD, USA
Economic Outcomes Research
5:15PM-6:15PM
W23: SENSITIVITY ANALYSIS IN COST-EFFECTIVENESS STUDIES: FROM GUIDELINES TO PRACTICE Discussion Leaders: Rahul Jain PhD, Assistant Professor, Department of Clinical and Administrative Pharmacy, University of Georgia, College of Pharmacy, Athens, GA, USA; Eberechukwu Onukwugha PhD, MS, Assistant Professor, Pharmaceutical Health Services Research Department, University of Maryland, School of Pharmacy, Baltimore, MD, USA; Michael J. Grabner PhD, Postdoctoral Fellow, Pharmaceutical Health Services Research Department, University of Maryland, School of Pharmacy, Baltimore, MD, USA
5:15PM-6:15PM
W24: WHEN THERE IS NO HEAD-TO-HEAD TRIAL: USING A PARTS APPROACH Discussion Leaders: Zeba Khan PhD, Vice President, Pricing and Market Access, Celgene, Summit, NJ, USA; J. Jaime Caro MD, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA
Health Care Policy Development Using Outcomes Research
W26: MARKET ACCESS IN THE LATIN AMERICAN CONTEXT: HOW FAR WILL THE STANDARD HEALTH ECONOMIC TOOLKIT CARRY YOU? Discussion Leaders: Joanna Campbell PhD, Senior Project Manager, Health Economics & Outcomes, i3Innovus, Medford, MA, USA; Gabriella Tannus Branco de Araújo MBA, Health Economics Director, AxiaBio Consulting, Sao Paulo, Brazil; Ximena Burbano MD, International Research Director, Zilonis, Boca Raton, FL, USA; David Thompson PhD, Vice President, Global Health Economics, i3 Innovus, Medford, MA, USA
Patient-Reported Outcomes/PREFERENCE-BASED Research
W27: USING A CATALOGUE OF EQ-5D SCORES TO MODEL QALYS FOR COST-EFFECTIVENESS ANALYSES Discussion Leaders: Patrick Sullivan PhD, MA, Associate Professor, Regis University, Rueckert-Hartman College for Health Professions, Denver, CO, USA; Mark J. Sculpher PhD, Health Economics and Director of the Programme on Economic Evaluation and Health Technology Assessment, Centre for Health Economics, The University of York, York, UK; Julia F. Slejko, PhD Candidate, University of Colorado Denver, Aurora, CO, USA; Vahram H. Ghushchyan PhD, Professional Research Assistant, University of Colorado Denver, Aurora, CO, USA
USE OF REAL WORLD DATA
5:15PM-6:15PM
W28: REGISTRIES AND EVIDENCE DEVELOPMENT Discussion Leaders: Richard Gliklich MD, President and CEO, Outcome, Cambridge, MA, USA; Jean Slutsky PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA
6:15PM-7:15PM
POSTER AUTHOR DISCUSSION HOUR – SESSION II
6:15PM-8:00PM
EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
ISPOR SOCIAL EVENT: ISPOR 15th ANNIVERSARY CELEBRATION PARTY (Free to all meeting attendees) Featuring music by the ISPOR Band – the Monte Carlos & dancing
Scott D. Ramsey MD, PhD